Albumin Market Outlook:
Albumin Market size is valued at USD 7.9 billion in 2025 and is projected to reach USD 15.1 billion by the end of 2035, rising at a CAGR of 7.5% during the forecast period, i.e., 2026-2035. In 2026, the industry size of albumin is estimated at USD 8.4 billion.
The international market is growing due to the growing demand for albumin in various therapeutic areas such as liver disease, burns, trauma, and surgical applications, where it finds its importance in fluid resuscitation. The population of patients receiving albumin treatment is, however, skewed toward the critically ill and tends to get clustered in tertiary care hospitals and big dialysis or ICU centers. On the supply side, the chain of activities includes plasma collection, fractionation, purification, fill finish, and cold-chain logistics. Supply knowledge encompasses plasma collection, fractionation, purification, and cold-chain logistics for drug and API manufacturing. According to a report by the World Integrated Trade Solution, in 2023, the U.S. imports of albumins and albuminates were worth USD 133,320 million with an import volume of 10,226,500 kg in 2023, showing strong demand in the healthcare sector.
The albumin market has many more operative functions in human physiology and is also a matter of concern for the pharmaceutical industry. As per a report by NLM in December 2022, the liver hepatocytes synthesize albumin and quickly excrete it into the bloodstream at a considerable rate of 10 to 15 grams per day, showing how important albumin is anatomically. Additionally, the market operates within the framework and market forces that influence the pharmaceutical industry. Intense research and development are carried out in recombinant albumin production platforms and purity assay developments to assure product quality.
